SCHEMBL2157251

SCHEMBL2157251

COc1ccc(N2CCN(S(C)(=O)=O)CC2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.71
LMNA P02545 1/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
ALDH1A1 P00352 2/20 0.61
PKM P14618 2/20 0.61
MAPK1 P28482 2/20 0.59
HSD11B1 P28845 1/20 0.59
MAPT P10636 3/20 0.58
GAA P10253 2/20 0.58
POLB P06746 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.55
KMT2A Q03164 2/20 0.55
THRB P10828 1/20 0.54
MEN1 O00255 1/20 0.54
ACLY P53396 1/20 0.54
NPC1 O15118 1/20 0.54
PKLR P30613 1/20 0.54
RAB9A P51151 1/20 0.54
HTR3E A5X5Y0 1/20 0.54
HTR3B O95264 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2448205 0.85 SMN1; SMN2 (0.53) TSHRLMNASMN1; SMN2ALDH1A1PKM
SCHEMBL19615056 0.85 SMN1; SMN2 (0.53) TSHRLMNASMN1; SMN2ALDH1A1PKM
SCHEMBL5501832 0.85 LMNA (0.69) TSHRLMNASMN1; SMN2ALDH1A1PKM
SCHEMBL28599511 0.83 HTR3E (0.73) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL29656856 0.83 HTR3E (0.73) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL2155738 0.82 NPSR1 (0.59) TSHRLMNASMN1; SMN2ALDH1A1MAPT
SCHEMBL2154830 0.82 MAPT (0.63) SMN1; SMN2ALDH1A1PKMMAPTGAA
SCHEMBL2155221 0.82 MAPT (0.58) TSHRLMNASMN1; SMN2ALDH1A1PKM
SCHEMBL12463334 0.81 LMNA (0.64) TSHRLMNASMN1; SMN2ALDH1A1PKM
SCHEMBL82680 0.80 MEN1 (0.69) TSHRLMNASMN1; SMN2ALDH1A1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1828160-B1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS MERCK SERONO SA (CH) 2011-12-14 EP disclosed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US disclosed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US disclosed
US-7973039-B2 3-(1,3-benzodioxol-5-yl)-1-({[4-(4-fluorophenyl)-1-piperazinyl]sulfonyl}methyl)-2-propynyl(hydroxy)formamide; analgesics, anticarcinogenic agents, antiarthritic agents; matrix metalloproteinase inhhibitors MERCK SERONO SA (CH) 2011-07-05 US disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US disclosed
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof MERCK SERONO SA (CH) 2008-08-14 US disclosed
CN-101124213-A Sulfonylamino cyclic derivatives and uses thereof SERONO LAB (CH) 2008-02-13 CN disclosed
EP-1828160-A1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF AS MMP INHIBITORS LABORATOIRES SERONO S.A. (CH) 2007-09-05 EP disclosed
WO-2006067114-A1 SULFONYL AMINO CYCLIC DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194520-A1 Sulfonyl Amino Cyclic Derivatives and Use Thereof GLS2, SRM, GLS TSHR 1187/4885LMNA 3423/4885SMN1; SMN2 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.